Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study - PubMed
3 hours ago
- #Blinatumomab
- #Acute Lymphoblastic Leukemia
- #Consolidation Therapy
- Blinatumomab consolidation significantly improved outcomes for high-risk Ph-negative B-ALL patients.
- The study included 94 HR patients receiving blinatumomab vs. 90 historical controls.
- At 5 years, relapse incidence was lower (23% vs. 49%) and overall survival higher (79% vs. 60%) with blinatumomab.
- Blinatumomab enhanced MRD clearance and disease-free survival across most subgroups, except KMT2A-rearranged cases.
- No additional DFS advantage was seen in patients who underwent allogeneic stem cell transplantation.